Contrasting PACS Group (NYSE:PACS) & Pheton (NASDAQ:PTHL)

PACS Group (NYSE:PACS) and Pheton (NASDAQ:PTHL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Earnings and Valuation

This table compares PACS Group and Pheton”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29 billion	1.10	$191.54 million	$1.56	23.60
Pheton	$305,215.00	6.37	-$660,000.00	N/A	N/A

PACS Group has higher revenue and earnings than Pheton.

Analyst Ratings

This is a summary of current recommendations and price targets for PACS Group and Pheton, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0	2	5	0	2.71
Pheton	1	0	0	0	1.00

PACS Group presently has a consensus target price of $48.00, suggesting a potential upside of 30.36%. Given PACS Group’s stronger consensus rating and higher probable upside, analysts plainly believe PACS Group is more favorable than Pheton.

Profitability

This table compares PACS Group and Pheton’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Pheton	N/A	N/A	N/A

Summary

PACS Group beats Pheton on 8 of the 9 factors compared between the two stocks.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.